Screener
Sana Biotechnology SANA Accrued Expenses
Accrued Expenses at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,123 | $1,669 |
| Accrued compensation | 7,584 | 13,240 |
| Accrued expenses and other current liabilities | 8,124 | 8,679 |
| Operating lease liabilities | 14,878 | 14,938 |
| Contingent consideration | 53,556 | 40,200 |
| Total current liabilities | 86,265 | 78,726 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's accrued expenses?
- Sana Biotechnology (SANA) reported accrued expenses of $7.58M in Q1 2026.
- How has Sana Biotechnology's accrued expenses changed year-over-year?
- Sana Biotechnology's accrued expenses decreased by 18.9% year-over-year, from $9.35M to $7.58M.
- What is the long-term trend for Sana Biotechnology's accrued expenses?
- Over 5 years (2020 to 2025), Sana Biotechnology's accrued expenses has grown at a -3.7% compound annual growth rate (CAGR), from $16.02M to $13.24M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Sana Biotechnology's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude